Affinity Technologies receives Japanese patent for CyPath Lung test to detect lung cancer early: San Antonio Saturday, October 10, 2026, 13:00 Hrs [IST] bioAffinity Technologie ...
The Japanese Patent Office has signalled its intention to grant patent protection for bioAffinity Technologies’ noninvasive ...
Lung cancer remains one of the malignancies with the highest incidence and mortality worldwide. Clinical practice has long been plagued by core dilemmas, including insufficient sensitivity in early ...
Lung cancer kills more people worldwide than any other malignancy, and the reason is painfully simple: it is usually caught ...
Affinity Technologies, Inc. ( (BIAF)) has issued an update. On October 8, 2026, bioAffinity Technologies announced that the Japan Patent Office issued a Notice of Allowance for a patent covering its ...
SAN ANTONIO, October 08, 2026--bioAffinity Technologies receives notice of allowance for new patent in Japan covering its noninvasive CyPath Lung diagnostic test for lung cancer.
Data presented at the 2026 AACR Annual Meeting demonstrated the promise of blood-based lung cancer detection via SimpleScreen Lung. Developers designed SimpleScreen Lung as an artificial intelligence ...
Affinity Technologies (Nasdaq: BIAF) soars after the Japan Patent Office issues a Notice of Allowance for its CyPath Lung ...